New York, Jan 19, 2026, 10:08 EST — Market closed
- Shares of Eli Lilly ended Friday up 0.5%, heading into a holiday-shortened week
- Traders are tracking early U.S. prescription data for Novo Nordisk’s new oral Wegovy, eyeing it as a potential indicator for Lilly
- The next test arrives when U.S. markets open Tuesday, spotlighting demand signals and pricing risks.
Eli Lilly and Company shares drew attention heading into Tuesday’s U.S. session, following a Friday close in the green. Investors digested new developments in the obesity-drug sector, a key driver behind the drugmaker’s recent surge.
The key question now: does the early appetite for new, easier-to-swallow weight-loss pills alter the game for established players, or just shuffle market share in a packed healthcare segment? For Lilly, minor tweaks in weekly prescription numbers can quickly sway sentiment, given that obesity and diabetes drugs are central to growth forecasts.
U.S. stock markets will be closed Monday in observance of Martin Luther King Jr. Day. That leaves investors to weigh their positions ahead of Tuesday’s open, relying more on headlines and weekend data than on any fresh price moves. 1
Lilly shares wrapped up Friday at $1,038.40, gaining $5.43 after slipping the day before. According to a table on the company’s investor site, roughly 3.8 million shares changed hands that day. 2
Traders are zeroing in on one key figure: early U.S. prescription numbers for Novo Nordisk’s new oral version of Wegovy. In its debut week, the pill racked up 3,071 prescriptions, just shy of Lilly’s Zepbound injection, which hit about 3,100. Analyst Umer Raffat described the launch as “solid,” according to 3 .
GLP-1 is the hormone pathway targeted by a class of diabetes and weight-loss drugs that reduce appetite and slow digestion. This category has become a key proxy for growth in big pharma, with any hint that these pills either broaden the market or create pricing pressure shaking both industry leaders and challengers alike.
Lilly markets the injectable drugs Zepbound for obesity and Mounjaro for diabetes, while developing its own oral obesity medication. The appeal of a pill is clear: fewer injections, wider potential use, and a fresh battleground in an already intense rivalry shaping the sector.
Early prescription numbers are often unreliable. They’re influenced by starter packs, insurance rules, supply bottlenecks, and basic stocking lags. A robust opening week doesn’t guarantee sustained demand.
Tuesday’s market open will focus on follow-up prescription data, fresh clues on payer coverage and pricing, and any new regulatory hints that might clarify the timeline for Lilly’s oral drugs. The first concrete catalyst arrives when regular trading resumes on Jan. 20.
